Last reviewed · How we verify
18F-metaFluorobenzylguanidine
18F-metaFluorobenzylguanidine is a radiopharmaceutical that selectively accumulates in neuroendocrine tumors, allowing for targeted imaging and therapy.
18F-metaFluorobenzylguanidine is a radiopharmaceutical that selectively accumulates in neuroendocrine tumors, allowing for targeted imaging and therapy. Used for Neuroblastoma, Pheochromocytoma, Paraganglioma.
At a glance
| Generic name | 18F-metaFluorobenzylguanidine |
|---|---|
| Also known as | IRP101 |
| Sponsor | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) |
| Target | Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by exploiting the high uptake of metaiodobenzylguanidine (MIBG) by certain neuroendocrine cells, which are often overexpressed in these tumors. This allows for the visualization and treatment of these tumors with high precision.
Approved indications
- Neuroblastoma
- Pheochromocytoma
- Paraganglioma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
- 18F-mFBG Imaging for Myocardial Sympathetic Innervation (PHASE2)
- 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: